adlitterio66339

About adlitterio66339

This author has not yet filled in any details.
So far adlitterio66339 has created 511 blog entries.

28 12, 2024

Qian Meng et al., Excessive erythrophagocytosis accounts for systemic inflammation in chronic kidney disease

adlitterio663392024-12-29T19:00:37+01:00

23 03, 2024

Giulia Paesello et al., Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

adlitterio663392024-03-23T12:42:34+01:00

22 03, 2024

Albino Eccher et al., Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing

adlitterio663392024-04-10T12:56:50+02:00

19 03, 2024

Marco Capezzone et al., Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer

adlitterio663392024-03-19T12:51:12+01:00

16 03, 2024

Melchior Linea et al., Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

adlitterio663392024-03-16T12:56:59+01:00

13 03, 2024

Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology

adlitterio663392024-03-15T15:53:41+01:00

27 02, 2024

Federica Di Maggio et al., A Novel DNA Variant in SMARCA4 Gene Found in a Patient Affected by Early Onset Colon Cancer

adlitterio663392024-02-27T14:15:40+01:00

20 02, 2024

Fabio Canino et al., Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

adlitterio663392024-02-20T14:28:58+01:00

20 02, 2024

Zahra Abrehdari-Tafreshi et al., The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients

adlitterio663392024-04-10T14:21:40+02:00

14 02, 2024

Lorenza Rimassa et al., Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

adlitterio663392024-02-14T14:34:18+01:00